Livongo Health, Inc. announced the findings of two studies that demonstrate how remote monitoring technologies can utilize continuous and unique data insights via its AI+AI engine to better inform care decisions and outcomes. The research findings were presented at the American Diabetes Association’s 80th Scientific Sessions: A Virtual Experience held on June 12-16, 2020. The first study, Predictors of Emergency Department and Inpatient Admissions after Hypo- and Hyperglycemic Events: Leveraging Remote Monitoring Data of People with Diabetes, included 7,633 study participants and used Livongo’s cellular-enabled blood glucose monitor and remote monitoring capabilities to determine specific predictors which may lead to a hypoglycemic or hyperglycemic event. The study determined that a gap in days between checking, more Missed Medication tags, fewer Before Breakfast tags, new users of oral diabetes medications, and other factors were predictors associated with future emergency department and inpatient visits due to a hypoglycemic event. It also found that models pairing blood glucose values with rich data including time of day, meal tags, medication use, and feeling tags are more likely to predict those who are at a higher-risk of costly care interventions than models using blood glucose data alone. The second study, Is Activation, Behaviors, and Attitudes to Managing Care Associated with Utilization of a Remote Diabetes Monitoring Platform (RDMP) and Improvement of A1c, was conducted in collaboration with Eli Lilly & Company and included 1,089 participants. The study found a direct correlation between improvements in Diabetes Empowerment Scale-Short Form (DES-SF) and increased platform utilization. In addition, participants who used the Livongo platform more regularly and those who achieved measurable improvements in Diabetes Distress Scale 17 (DDS17) experienced better glycemic control. Through its AI+AI engine, Livongo uses a connected ecosystem to aggregate data, which includes cellular-enabled devices and integration with continuous glucose monitors, and then applies advanced data science to create detailed Member profiles that includes personal health and medication trends. Livongo provides Members with cellular-enabled devices, supplies, and access to digital coaching and time with certified health coaches for real-time support and goal setting at no cost. Last year at the American Diabetes Association’s Scientific Sessions held in San Francisco, California, Livongo announced a separate study in collaboration with Eli Lilly & Company that demonstrated 94% of Livongo program Members who participated in a program survey achieved improved Diabetes Empowerment Scale – Short Form (DES-SF) or Diabetes Distress Scale 2 (DDS2) in year one; effectively improving confidence in diabetes self-management while decreasing burnout related to diabetes management.